Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 03:15PM ET
1.85
Dollar change
-0.00
Percentage change
-0.01
%
Index- P/E- EPS (ttm)-0.90 Insider Own5.15% Shs Outstand53.33M Perf Week-1.07%
Market Cap98.65M Forward P/E- EPS next Y-0.94 Insider Trans0.00% Shs Float50.58M Perf Month16.35%
Income-42.77M PEG- EPS next Q-0.16 Inst Own49.68% Short Float0.87% Perf Quarter26.71%
Sales0.00M P/S- EPS this Y54.82% Inst Trans-6.09% Short Ratio1.42 Perf Half Y24.99%
Book/sh0.45 P/B4.11 EPS next Y-49.68% ROA-50.37% Short Interest0.44M Perf Year-42.73%
Cash/sh1.43 P/C1.29 EPS next 5Y- ROE-162.87% 52W Range1.12 - 3.52 Perf YTD10.77%
Dividend Est.- P/FCF- EPS past 5Y-7.22% ROI-55.22% 52W High-47.45% Beta1.84
Dividend TTM- Quick Ratio15.40 Sales past 5Y-29.33% Gross Margin- 52W Low65.17% ATR (14)0.12
Dividend Ex-Date- Current Ratio15.40 EPS Y/Y TTM35.07% Oper. Margin- RSI (14)56.28 Volatility7.52% 8.16%
Employees47 Debt/Eq2.25 Sales Y/Y TTM-100.00% Profit Margin- Recom1.40 Target Price10.00
Option/ShortYes / Yes LT Debt/Eq2.23 EPS Q/Q59.36% Payout- Rel Volume0.43 Prev Close1.85
Sales Surprise- EPS Surprise13.85% Sales Q/Q- EarningsNov 12 BMO Avg Volume309.40K Price1.85
SMA20-0.54% SMA5012.84% SMA20017.60% Trades Volume119,345 Change-0.01%
Date Action Analyst Rating Change Price Target Change
Aug-22-24Initiated Rodman & Renshaw Buy $9
Jun-20-23Downgrade Jefferies Buy → Hold $8 → $4
Apr-22-22Upgrade Piper Sandler Neutral → Overweight $8 → $10
Mar-05-21Initiated H.C. Wainwright Buy $20
Jul-29-20Upgrade Oppenheimer Perform → Outperform $18
Jul-24-20Upgrade Jefferies Hold → Buy
Mar-25-20Downgrade Jefferies Buy → Hold $28 → $3
Mar-24-20Downgrade Piper Sandler Overweight → Neutral $26.50 → $3
Mar-24-20Downgrade Oppenheimer Outperform → Perform
Jun-04-19Initiated Oppenheimer Outperform $32
Nov-25-24 08:00AM
Nov-19-24 09:55AM
Nov-12-24 09:17AM
09:03AM
Sep-24-24 08:00AM
07:00AM Loading…
Sep-06-24 07:00AM
Sep-04-24 08:00AM
Sep-03-24 08:00AM
Aug-26-24 08:00AM
Aug-08-24 04:41PM
04:17PM
Jul-31-24 08:00AM
Jul-15-24 08:00AM
Jun-12-24 08:00AM
May-31-24 08:00AM
07:00AM Loading…
May-29-24 07:00AM
May-22-24 08:00AM
May-16-24 12:00PM
May-13-24 01:53PM
07:15AM
07:15AM
May-02-24 08:00AM
Apr-17-24 08:00AM
Apr-08-24 11:36AM
Apr-03-24 08:00AM
Apr-01-24 08:00AM
Mar-28-24 07:00AM
Mar-21-24 01:53PM
07:14AM
Feb-29-24 04:01PM
07:00AM Loading…
07:00AM
Feb-28-24 04:37PM
Feb-26-24 07:00AM
Jan-18-24 01:23PM
Jan-16-24 09:35AM
Dec-27-23 11:11AM
Dec-26-23 10:55AM
07:00AM
Nov-21-23 07:00AM
Nov-13-23 07:02AM
06:57AM
Nov-11-23 10:00AM
Nov-07-23 07:00AM
Oct-24-23 07:00AM
Oct-06-23 07:00AM
Sep-27-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 07:56AM
07:35AM
Aug-08-23 09:55AM
Jun-20-23 07:00AM
Jun-10-23 09:40AM
Jun-01-23 07:00AM
May-22-23 07:00AM
May-11-23 07:31AM
07:16AM
May-08-23 07:00AM
May-01-23 06:02AM
Apr-21-23 09:23AM
Apr-12-23 07:00AM
Mar-31-23 10:39AM
Mar-29-23 09:17AM
Mar-28-23 07:00AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Jan-16-23 12:00PM
Jan-01-23 08:33AM
Dec-13-22 09:35AM
Dec-02-22 02:11PM
Nov-29-22 07:00AM
Nov-22-22 07:00AM
Nov-12-22 07:47AM
Nov-10-22 07:21AM
Nov-07-22 12:13PM
Oct-25-22 07:00AM
Oct-22-22 08:21AM
08:05AM
Oct-20-22 09:35AM
Oct-18-22 06:30PM
Oct-17-22 09:14AM
09:12AM
06:00AM
Sep-11-22 03:13PM
Sep-06-22 07:00AM
Aug-10-22 04:15PM
Jul-24-22 10:28AM
Jun-02-22 07:00AM
May-27-22 05:03PM
May-23-22 06:23AM
May-17-22 07:00AM
May-12-22 07:15AM
Apr-30-22 09:00AM
Apr-15-22 04:41PM
10:20AM
Apr-14-22 07:00AM
Mar-24-22 07:20AM
Mar-01-22 07:00AM
Feb-16-22 07:00AM
Feb-14-22 01:03PM
Jan-04-22 07:00AM
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.